{"entity":{"id":"xpert-bladder-cancer-monitor","kind":"drug","name":"Xpert Bladder Cancer Monitor","aka":["Xpert BC Monitor","Cepheid Xpert Bladder"],"tldr":"A urine test that reads five RNA markers to check for bladder cancer coming back, and in a Danish trial halved the number of camera examinations of the bladder.","summary":"Cepheid describes \"a non-invasive biomarker test for monitoring NMIBC patients for recurrence in conjunction with other clinical measures\" built on \"the five strongest bladder cancer indicator mRNAs\", with a CE-IVD package insert. In the randomised DaBlaCa-15 trial in high-grade non-muscle-invasive bladder cancer, 1,029 cystoscopies were performed in the control arm and 445 in the arm guided by the test, the risk difference for high-grade recurrence was 0.08 per cent (95% CI minus 7.2 to 7.4), and two pTa high-grade recurrences were missed (Dreyer 2025). A longitudinal validation reported 87 per cent sensitivity for high-grade cancer and a negative predictive value of 99 per cent (Cowan 2021).","status":"established","asOf":"2026-11-04","links":[{"label":"Cepheid: Xpert Bladder Cancer Monitor","url":"https://www.cepheid.com/en-GB/tests/oncology-human-genetics/expert-bladder-cancer-monitor.html"}],"tags":["test","rna"],"related":["cxbladder"],"cancers":["non-muscle-invasive-bladder-cancer","urothelial"],"sections":[],"technologies":["liquid-rna-biopsy","urine-bladder-cancer-tests"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-dreyer-xpert-bladder-dablaca-15-eur-urol-2025","paper-cowan-xpert-bladder-monitor-bju-int-2021"],"journals":[],"dependsOn":[],"notes":[],"brand":"Xpert Bladder Cancer Monitor","modality":"Urine mRNA test (five markers, bladder cancer surveillance; CE-IVD)","mechanism":"A cartridge test measures five mRNA markers in voided urine to flag likely recurrence of non-muscle-invasive bladder cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/xpert-bladder-cancer-monitor/","neighbours":{"drug":[{"id":"cxbladder","kind":"drug","name":"Cxbladder","route":"/drugs/cxbladder/"}],"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"technology":[{"id":"liquid-rna-biopsy","kind":"technology","name":"Liquid RNA biopsy (cell-free, vesicle and platelet RNA)","route":"/technologies/liquid-rna-biopsy/"},{"id":"urine-bladder-cancer-tests","kind":"technology","name":"Urine tests for bladder cancer (cytology, FISH, RNA and methylation)","route":"/technologies/urine-bladder-cancer-tests/"}],"paper":[{"id":"paper-cowan-xpert-bladder-monitor-bju-int-2021","kind":"paper","name":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer","route":"/key-papers/paper-cowan-xpert-bladder-monitor-bju-int-2021/"},{"id":"paper-dreyer-xpert-bladder-dablaca-15-eur-urol-2025","kind":"paper","name":"Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial","route":"/key-papers/paper-dreyer-xpert-bladder-dablaca-15-eur-urol-2025/"}]}}